BRIEF-Catalyst Pharma finalizes late-stage trial design with FDA for Firdapse
June 13, 2016 at 08:31 AM EDT
* Catalyst Pharmaceuticals announces agreement with FDA on confirmatory phase 3 study protocol for Firdapse in Lambert-Eaton Myasthenic Syndrome
